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Summary In order to evaluate long-term somatic morbidity after treatment for testicular cancer 149 patients
with NED > 3 years answered a questionnaire. The patients had been treated with surgery only (32 patients),
radiotherapy only (39 patients), cisplatin-based chemotherapy plus surgery (46 patients) or chemotherapy plus
radiotherapy with or without surgery (32 patients). Raynaud-like phenomena were the most frequent side-
effect occurring significantly more often after cisplatin-based chemotherapy than after surgery or radiotherapy
(33/72 patients versus 5/68 patients). Peripheral sensory 'neuropathy' was reported by 18% of all the patients.
Seventeen per cent and 11% complained of pulmonary symptoms and auditory symptoms, respectively.
Gastrointestinal side-effects were more frequent after any type of cytotoxic therapy than after surgery only
(34/47 patients versus 5/22 patients). Twenty-six patients had fathered children after treatment. About 80% of
the patients were in full time wage-earning activity when they answered the questionnaire. In conclusion, 3-7
years after treatment for testicular cancer, 30-50% of the patients had minor somatic complaints whereas
serious side-effects seldom occurred.
About 90% of the patients with testicular cancer are cured
today. Most patients will accept a high degree of acute
toxicity if this is the price to pay for cure. It is, however,
essential to keep long-term side-effects to a minimum.
Only limited systematic information is available about the
type and frequency of problems testicular cancer patients
experience several years after the different modern treatment
modalities. The present report is an evaluation of somatic
side-effects and morbidity in disease-free testicular cancer
patients.
Patients and methods
The Royal Marsden staging system for testicular cancer has
been used at our institution since 1978 (Peckham et al.,
1979). The treatment principles are as follows.
Seminoma
Clinical stage I, II A/B: infradiaphragmatic radiotherapy
36-40 Gy (Fossa et al., 1989a).
Clinical stage > II C: Cisplatin-based combination
chemotherapy (CVB: cisplatin, vinblastine, bleomycin
(modified Einhorn regimen)) followed by radiotherapy/
surgery to initial tumour-bearing regions (Fossa et al., 1987).
Non-seminoma
Clinical stage I, II A: retroperitoneal lymph node dissection
(RLND) followed by three to four cycles of CVB in case of
metastases.
Clinical stage > II B: CVB followed by surgery of residual
masses within initial tumour-bearing areas (exceptionally in
1978-80 radiotherapy). During 1978-79 non-seminoma
patients received maintenance chemotherapy with CCNU/
vinblastine (Klepp et al., 1984).
In 1985 a questionnaire was mailed to 160 testicular cancer
patients with no evidence of disease for at least 3 years.
These patients represented a consecutive series of patients
referred to the hospital for primary treatment from 1978 to
1981 and who had finished their treatment before 1 April
1982.
One hundred and fourty-nine patients (93%) answered the
questionnaire, which dealt with the patients' gastrointestinal,
neurological, pulmonary and audiological status as well as
post-treatment paternity, psychosocial and sexual problems
(Table I). The two latter topics are the subject of another
paper (S. Kaasa et al., in preparation). The patients' records
were reviewed for supplementary information.
The patients, 11 of whom were treated for relapse, were
divided into four subgroups with regard to their treatment
(Tables II and III): subgroup 1, unilateral retroperitoneal
lymphnode dissection (RLND) (32 patients); subgroup 2,
infradiaphragmatic radiotherapy (39 patients); subgroup 3,
cisplatin-based combination chemotherapy plus RLND (46
patients); subgroup 4, cisplatin-based combination
chemotherapy plus infradiaphragmatic radiotherapy with or
without surgery (mostly RLND) (32 patients).
Statistics
The x2 test was applied to assess differences of distributions.
A P value of less than 0.05 was regarded as statistically
significant.
Results
Raynaud-like phenomena were the most frequent somatic
side-effect. They were reported significantly more often in
patients treated with cisplatin based chemotherapy than in
the other subgroups (P<0.001) (Table IV). Peripheral sens-
ory 'neuropathy', which was observed in 18% of all patients,
was significantly more often reported by the patients treated
with both chemotherapy and radiotherapy (subgroup 4) than
by the three other groups combined (P<0.001). Pulmonary
symptoms were recorded in 17% of the patients and auditory
symptoms in 11%. Patients in subgroup 4 had, in general, a
higher frequency of these side-effects than the other patients,
but the differences were not statistically significant.
Gastrointestinal side-effects were reported by about 40%
of all patients. A special analysis was done for 109 patients
who stated in the questionnaire that they had not had gastro-
intestinal symptoms before they were treated for testicular
cancer. Thirty-five per cent of these patients had some kind
of gastrointestinal problem in 1985 (Table V). Patients in
subgroup 4 (chemotherapy combined with radiotherapy)
reported gastrointestinal side-effects most often. The most
frequent complaints among all patients were meteorism
(33%), diffuse abdominal pain (15%) and diarrhoea (13%)
(Table V). Patients treated with abdominal radiotherapy
complained more often about nausea and vomiting than
those who had received no irradiation.
Twenty-five per cent of the patients required medication,
mostly for digestive problems or cardiovascular disease.
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Table I An example of
Side-effect
Peripheral sensory
'neuropathy'
Raynaud-like phenomena
Auditory symptoms
Pulmonary toxicity
questions used to assess somatic side-
effects
Abbreviated questions
Reduced cutaneous sensibility in hands
and/or feet.
Troublesome pricking or tingling in
arms and/or legs.
White fingers and/or toes in cold
weather.
Decreased hearing acuity.
Buzzing in the ears.
Dizziness.
Cough.
Expectoration.
Shortness of breath at rest, when walk-
ing on flat ground and/or when wal-
king uphill.
Eight of nine patients using medication for digestive prob-
lems had been irradiated. Three patients from subgroups 2
and 3 and two patients from subgroup 4 regularly used drugs
for cardiovascular illness. Other medication used by patients
in the study included testosterone by six patients, and
tranquillisers/hypnotics by six patients. The overall drug con-
sumption was highest in subgroup 4, especially among
patients treated for relapse, but the difference was not statis-
tically significant.
Eighty-six of the 149 patients had children before treat-
ment for testicular cancer (Table VI). Twenty-six became
fathers of 29 children after treatment. Nineteen of these
patients had undergone retroperitoneal lymph node dissec-
tion, mostly unilateral. None of the patients who had been
treated with both chemotherapy and radiotherapy had
fathered children after treatment. The patients who had not
become fathers were asked about possible reasons. Fifty
patients stated that they did not want to have children.
Significantly more patients from subgroup 2 did not want to
father children after treatment compared to patients from the
other subgroups. A total of 63 patients indicated that they in
the future perhaps would like to father children. Forty-six
patients thought they were infertile, most of them from sub-
groups 3 and 4.
Table II Patient characteristics
Subgroup I Subgroup 2 Subgroup 3 Subgroup 4 Total
No. of patients 32 39 46 32 149
Seminoma 0 32 1 13 46
Non-seminoma 32 7 45 19 103
Initial stage
Ma 0 0 1 2 3
1 32 38 0 6 76
11 0 1 29 18 48
III 0 0 2 2 4
IV 0 0 14 4 18
Relapse 0 0 1 10 11
Age at start of
treatment (years)
Mean 31.9 40.7 28.9 35.5 34.0
Range 18-58 17-64 17-57 20-64 17-64
Time from start of
treatment to
answering questionnaire
(years)
Mean 4.5 4.9 5.0 6.3 5.1
Range 3-6 3-7 4-9 4-9 3-9
aElevated tumour markers, but no metastases were found.
Table III Treatment characteristics
Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4 Total
RLND8 32 0 39 12 83
Abdominal radio-
therapy
<40 Gy 0 31 0 20 51
>40 Gy 0 8 0 12 20
Chemotherapy
CVB 2 cycles 0 0 1 0 1
3 cycles 0 0 13 2 15
4 cycles 0 0 28 28 56
>4 cycles 0 0 4 2 6
Other cisplatin-
based combination
chemotherapy 0 0 3 9 12
Combination
chemotherapy
without cisplatin 0 0 10 19 29
Duration of treatment
(months)
Mean 1.0 1.9 8.5 16.0 6.8
Range 1.0 1-3 3-48 5-37 1-48
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Table IV Late somatic side-effects in patients with no symptoms before therapy
Subgroup I Subgroup 2 Subgroup 3 Subgroup 4 Total
(32)a (39) (46) (32) (149)
Raynaud-like
phenomena
Yes 4 1 18 15 38
No 28 35 24 15 102
Peripheral sensory
'neuropathy'
Yes 5 2 8 11 26
No 26 34 36 21 117
Pulmonary
symptoms
Yes 3 3 8 7 21
No 25 29 34 16 104
Auditory symtoms
Yes 2 2 5 5 14
No 28 32 37 20 117
aTotal number ofpatients in each subgroup. The total number of alternatives can be less than the total
number of patients within each subgroup due to lack of answers.
Table V Gastrointestinal toxicity in patients with no gastrointestinal symptoms before therapy
Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4 Total
(32)a (39) (46) (32) (149)
Gastrointestinal
toxicity
Yes 5 10 11 13 39
No 18 17 25 10 70
Nausea
Yes 1 6 2 4 13
No 26 27 37 21 111
Vomiting
Yes 0 5 1 4 10
No 26 27 39 20 112
Meteorism
Yes 5 8 12 13 38
No 20 21 25 10 76
Abdominal pain
Yes 1 5 5 17 18
No 24 25 34 17 100
Diarrhoea 4
Yes 0 23 4 7 15
No 25 35 21 104
Constipation 2
Yes 0 28 2 2 6
No 26 36 22 112
aTotal number ofpatients in each subgroup. The total number ofalternatives can be less than the total
number of patients within each subgroup due to lack of answers.
One hundred and twenty-three patients stated that their
general health was good or very good. Problems with general
health could not be correlated to the type of therapy given,
to the duration of treatment or to the age of the patients
(data not shown).
When answering the questionnaire 115 patients were in
full-time wage-earning activity and 11 had a part-time job.
Of the 34 patients who were not in full time income-
producing activity eight were learning a profession or doing
military service, two were unemployed and two had retired
due to high age. Seventeen patients had received disability
pension, and for eight the pension was related to the previous
malignant disease. Six of the latter patients had been treated
with both chemotherapy and radiotherapy. Eighty-four
patients had been on sick leave at least once during the year
before answering the questionnaire, without statistical
difference between the subgroups. For the majority of
patients this was a short-lasting absence.
Disscussion
Few reports have systematically evaluated the frequency and
type of long-term somatic side-effects after modern treatment
for testicular cancer. Most of the published reports are based
on routine information from the medical records which
usually only describe more severe toxicity. This might lead to
under-reporting of moderate or mild degrees of morbidity
(Fossa et al., 1989b). Only specially designed studies address-
ing long-term toxicity will provide detailed information about
mild degrees of side-effects and their influence on the
patients' quality of life.
The results presented in this study are based on answers
given to a questionnaire, and thus represent the patients'
subjective somatic problems. As supplementary clinical
examinations were not routinely performed, diagnostic inter-
pretation of the symptoms should be made with great
caution. Not all symptoms reported by the patients in the154 N. AASS et al.
Table VI Paternity
Subgroup I Subgroup 2 Subgroup 3 Subgroup 4 Total
(32)a (39) (46) (32) (149)
Paternity before
treatment 20 28 20 18 86
Paternity after
treatment 14 5 7 0 26
No. of children born
after treatment 15 6 8 0 29
Reasons for not
fathering children
after treatment:
Children not
wanted 8 23 10 9 50
'Infertile' 5 3 20 18 46
Partner 'infertile' 1 3 2 0 6
Ambiguous 2 1 3 5 11
aTotal number ofpatients in each subgroup. The total number of alternatives can be less than the total
number of patients within each subgroup due to lack of answers.
present study are necessarily caused by previous treatment
for testicular cancer. However, intergroup variations may
indicate a possible relationship between treatment and symp-
toms.
In the present study Raynaud-like phenomena (described
here as white fingers and toes on exposure to cold) were
reported in about 45% of the patients who had received
chemotherapy. Although some of these complaints may have
other explanations, the majority most likely represent
Raynaud's phenomena in accordance with the observations
of Vogelzang et al., (1985) and Roth et al. (1988). The
mechanism(s) for development of Raynaud-like phenomena
after chemotherapy treatment are still uncertain (Doll et al.,
1986). Contrary to Vogelzang et al.'s observation (1981) we
did not find any correlation with smoking habits. Four of the
32 patients who received only surgical treatment also
reported Raynaud-like phenomena. Three of these patients
emphasised that their symptoms were limited to their feet.
Thrombangitis obliterans was diagnosed in one of them. In
two patients, both of whom had undergone unilateral
RLND, supplementary investigations revealed autonomic
dysfunction in the contralateral leg.
Five of 31 patients from subgroup 1 (RLND only)
reported symptoms of peripheral sensory 'neuropathy'. Sur-
prisingly, the frequency of peripheral sensory 'neuropathy'
did not increase when only three to four cycles of
chemotherapy were given in addition to surgery (subgroup
3). However, the combination of radiotherapy and
chemotherapy seems particularly detrimental with regard to
this side-effect.
No effective treatment exists for Raynaud-like phenomena
and peripheral neuropathy. Fortunately the symptoms seem
to subside spontaneously with time in some patients, while
others gradually get accustomed to them. However, in some
patients these side-effects remain disabling, forcing individual
patients to change their employment. In an attempt to reduce
the neurological side-effects vinblastine has been replaced by
VP-16 in the chemotherapy given to testicular cancer
patients. This has reduced the acute toxicity (Williams et al.,
1987) and will, it is hoped, lead to a decrease in long-term
side-effects.
Diffuse abdominal symptoms are common, with roughly
one-third of the general population reporting minor
abdominal symptoms, such as alternating stools, disturbing
abdominal rumbling and colic (Hollnagel et al., 1982; Nyren,
1985). Though our results are not quite comparable to these
reports due to different evaluation methods, our overall
percentage of 40% reporting gastrointestinal symptoms after
therapy does not seem to be particularly high. However, 35%
of the patients who had no symptoms before therapy
developed gastrointestinal disturbances after treatment.
Moderate to severe degrees of post-irradiation gastrointes-
tinal side-effects are well known from the literature (Roswit
et al., 1972; Hanks et al., 1981; Gallez-Marchal et al., 1984;
Langlois et al., 1985; Coia et al., 1988), and a dose-response
relationship has been shown (Friedman et al., 1952; Coia et
al., 1988; Fossa et al., 1989b). The increased risk of develop-
ing such toxicity is demonstrated in our study by the fact
that eight of nine patients who regularly used medications for
diverse digestive disorders had been irradiated. Dependent on
fractionation schemes, total dose, treatment volume and
observation time about 5-9% of irradiated patients will
develop moderate to severe post-treatment gastrointestinal
disorders (Hamilton et al., 1987; Coia et al., 1988), and in
5-9% peptic ulcer is found (Hamilton et al., 1982; Fossa et
al., 1989b. The frequency of gastrointestinal toxicity reported
from other studies is thus lower than found in the present
series in which mild degrees of toxicity are also evaluated.
Based on our study, the combination of radiotherapy and
cytostatic drugs in particular seems to increase the number of
moderate to severe gastrointestinal problems, a finding which
is contradictory to other reports.
Infertility is one of the major concerns in testicular cancer
patients, especially in the younger non-seminoma patients.
The problem is partly due to the germ cell malignancy per se,
but is also related to the type and intensity of treatment, as
demonstrated by comparing subgroup 1 with subgroups 3
and 4. From previous studies it is known that three to four
cycles ofcisplastin-based chemotherapy, as given in subgroup
3, allow recovery of spermatogenesis (Fossa et al., 1985a). It
is primarily the extent of retroperitoneal surgery and the
frequency of 'dry ejaculation' which reduce the chances for
post-treatment paternity. Probably the combination of
chemotherapy and radiotherapy also play an important but
less significant role. Although not specifically addressed in
the present study, we know from previous studies that
80-90% of the patients undergoing bilateral RLND
(majority of patients in subgroup 3) have 'dry ejaculation',
compared to only 20% in patients operated with unilateral
RLND (subgroup 1) (Fossa et al., 1985b). It is hoped that
recently developed nerve-sparing techniques for RLND will
allow more young non-seminoma patients to father children
after treatment for metastatic testicular cancer.
Ototoxicity is a well-known side effect after treatment with
cisplatin, and its frequency increases with increasing
cumulative dose (von Hoff et al., 1979; Loehrer et al., 1984).LONG-TERM MORBIDITY TESTICULAR CANCER 155
However, the present study shows that high frequency hear-
ing loss caused by cisplatin is not noticed by most of the
patients. Bleomycin-induced decreased lung function was not
a major problem for our patients as observed by others
(Ginsberg et al., 1982; van Barneveld et al., 1985). One
reason may be that our cumulative bleomycin dose did not
exceed 300 mg.
In conclusion, the long-term somatic side-effects 3-7 years
(mean 4.6 years) after treatment for testicular cancer were on
an acceptable level. Few serious complications were reported.
However, 30-50% of the patients developed minor somatic
complaints which did not seem to affect their general health.
In the future one should avoid treatment with both
chemotherapy and radiotherapy as this combination in-
creases the frequency of late toxicity. Furthermore, RLND
should be as limited as possible in order to preserve fertility.
In general, low risk groups and high risk groups of patients
should be identified. Less treatment can probably be given to
the former whereas intensive treatment is necessary for the
latter.
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